UPCNasdaqPharmaceutical PreparationsFiscal year ends September 30
Universe Pharmaceuticals INC
Financials through fiscal 2025, year ended Sep 30, 2025Last filing: 20-F on Jan 29, 2026
$3.76−0.17 (-4.33%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Universe Pharmaceuticals INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | % of revenue | YoY |
|---|---|---|---|---|---|
| Revenue from sales of self-manufactured TCMD products [Member] | $13.26B | $14.03B | $18.57B | 74.3% | -5.5% |
| Revenue from sales of third-party products [Member] | $4.60B | $9.00B | $13.74B | 25.7% | -48.9% |
By region
From the segment and revenue-disaggregation notes of Universe Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.